Overexpression of α-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas

Histopathology

Volumn 58, Issue 5, 2011, Pages 712-719

  Sekine, Shigeki ^a   Ogawa, Reiko ^a   Ojima, Hidenori ^a   Kanai, Yae ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

catenin; AMACR; Hepatocellular carcinoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BETA CATENIN;

ADULT; AGED; ARTICLE; BILE ACID METABOLISM; CANCER GENETICS; CLINICAL ARTICLE; CORRELATION ANALYSIS; CTNNB1 GENE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RACEMASES AND EPIMERASES;

EID: 79954480164     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03798.x     Document Type: Article

References (28)

1. Lloyd MD, Darley DJ, Wierzbicki AS et al. Alpha-methylacyl-CoA racemase - an 'obscure' metabolic enzyme takes centre stage. FEBS J. 2008; 275; 1089-1102.
2. Xu J, Stolk JA, Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000; 60; 1677-1682.
3. Jiang Z, Woda BA, Rock KL et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol. 2001; 25; 1397-1404.
4. Rubin MA, Zhou M, Dhanasekaran SM et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287; 1662-1670.
5. Zha S, Ferdinandusse S, Denis S et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 2003; 63; 7365-7376.
6. Jiang Z, Fanger GR, Woda BA et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum. Pathol. 2003; 34; 792-796.
7. Went PT, Sauter G, Oberholzer M et al. Abundant expression of AMACR in many distinct tumour types. Pathology 2006; 38; 426-432.
8. Guzman G, Wu SJ, Kajdacsy-Balla A et al. Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes. Appl. Immunohistochem. Mol. Morphol. 2006; 14; 411-416.
9. Li W, Cagle PT, Botero RC et al. Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2008; 27; 2.
10. Miyoshi Y, Iwao K, Nagasawa Y et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 1998; 58; 2524-2527.
11. de La Coste A, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 1998; 95; 8847-8851.
12. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 2006; 281; 22429-22433.
13. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275; 1787-1790.
14. Cadoret A, Ovejero C, Terris B et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002; 21; 8293-8301.
15. Loeppen S, Schneider D, Gaunitz F et al. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res. 2002; 62; 5685-5688.
16. Loeppen S, Koehle C, Buchmann A et al. A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 2005; 26; 239-248.
17. Cavard C, Terris B, Grimber G et al. Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene 2006; 25; 599-608.
18. Renard CA, Labalette C, Armengol C et al. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res. 2007; 67; 901-910.
19. Yamamoto Y, Sakamoto M, Fujii G et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 2003; 37; 528-533.
20. Audard V, Grimber G, Elie C et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J. Pathol. 2007; 212; 345-352.
21. Sekine S, Lan BY, Bedolli M et al. Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology 2006; 43; 817-825.
22. Ferdinandusse S, Denis S, Dacremont G et al. Toxicity of peroxisomal C27-bile acid intermediates. Mol. Genet. Metab. 2009; 96; 121-128.
23. Ferdinandusse S, Denis S, Clayton PT et al. Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat. Genet. 2000; 24; 188-191.
24. Setchell KD, Heubi JE, Bove KE et al. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 2003; 124; 217-232.
25. Benhamouche S, Decaens T, Godard C et al. Apc tumor suppressor gene is the 'zonation-keeper' of mouse liver. Dev. Cell 2006; 10; 759-770.
26. Hailfinger S, Jaworski M, Braeuning A et al. Zonal gene expression in murine liver: lessons from tumors. Hepatology 2006; 43; 407-414.
27. Sekine S, Gutierrez PJ, Lan BY et al. Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology 2007; 45; 361-368.
28. Sekine S, Ogawa R, McManus MT et al. Dicer is required for proper liver zonation. J. Pathol. 2009; 219; 365-372.